Literature DB >> 20620168

Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza.

Bruce Y Lee1, Rachel R Bailey, Ann E Wiringa, Abena Afriyie, Angela R Wateska, Kenneth J Smith, Richard K Zimmerman.   

Abstract

Employers may be loath to fund vaccination programs without understanding the economic consequences. We developed a decision analytic computational simulation model including dynamic transmission elements that estimated the cost-benefit of employer-sponsored workplace vaccination from the employer's perspective. Implementing such programs was relatively inexpensive (<$35/vaccinated employee) and, in many cases, cost saving across diverse occupational groups in all seasonal influenza scenarios. Such programs were cost-saving for a 20% serologic attack rate pandemic scenario (range: -$15 to -$995) per vaccinated employee) and a 30% serologic attack rate pandemic scenario (range: -$39 to -$1,494 per vaccinated employee) across all age and major occupational groups. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20620168      PMCID: PMC2926133          DOI: 10.1016/j.vaccine.2010.07.003

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

1.  Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company.

Authors:  E Burckel; T Ashraf; J P de Sousa Filho; E Forleo Neto; H Guarino; C Yauti; B Barreto F de; L Champion
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 2.  Sickness absence due to influenza.

Authors:  F W O'Reilly; A B Stevens
Journal:  Occup Med (Lond)       Date:  2002-08       Impact factor: 1.611

3.  Impact of influenza vaccination on civilian aircrew illness and absenteeism.

Authors:  Marias A G Mixéu; Glaucia N R Vespa; Eduardo Forleo-Neto; João Toniolo-Neto; Paulo M Alves
Journal:  Aviat Space Environ Med       Date:  2002-09

4.  Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.

Authors:  Li M Ling; Angela L Chow; David C Lye; Adriana S Tan; Prabha Krishnan; Lin Cui; Nwe N Win; Monica Chan; Poh L Lim; Cheng C Lee; Yee S Leo
Journal:  Clin Infect Dis       Date:  2010-04-01       Impact factor: 9.079

5.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.

Authors:  C B Bridges; W W Thompson; M I Meltzer; G R Reeve; W J Talamonti; N J Cox; H A Lilac; H Hall; A Klimov; K Fukuda
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

6.  Economic costs of influenza-related work absenteeism.

Authors:  Manabu Akazawa; Jody L Sindelar; A David Paltiel
Journal:  Value Health       Date:  2003 Mar-Apr       Impact factor: 5.725

7.  Alternative vaccination locations: who uses them and can they increase flu vaccination rates?

Authors:  Bruce Y Lee; Ateev Mehrotra; Rachel M Burns; Katherine M Harris
Journal:  Vaccine       Date:  2009-05-09       Impact factor: 3.641

Review 8.  Does influenza transmission occur from asymptomatic infection or prior to symptom onset?

Authors:  Eleni Patrozou; Leonard A Mermel
Journal:  Public Health Rep       Date:  2009 Mar-Apr       Impact factor: 2.792

9.  Use of, effectiveness of, and attitudes regarding influenza vaccine among house staff.

Authors:  Richard T Lester; Allison McGeer; George Tomlinson; Allan S Detsky
Journal:  Infect Control Hosp Epidemiol       Date:  2003-11       Impact factor: 3.254

10.  Viral shedding and clinical illness in naturally acquired influenza virus infections.

Authors:  Lincoln L H Lau; Benjamin J Cowling; Vicky J Fang; Kwok-Hung Chan; Eric H Y Lau; Marc Lipsitch; Calvin K Y Cheng; Peter M Houck; Timothy M Uyeki; J S Malik Peiris; Gabriel M Leung
Journal:  J Infect Dis       Date:  2010-05-15       Impact factor: 5.226

View more
  18 in total

1.  Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger.

Authors:  Bruce Y Lee; Tina-Marie Assi; Jayant Rajgopal; Bryan A Norman; Sheng-I Chen; Shawn T Brown; Rachel B Slayton; Souleymane Kone; Hailu Kenea; Joel S Welling; Diana L Connor; Angela R Wateska; Anirban Jana; Ann E Wiringa; Willem G Van Panhuis; Donald S Burke
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

Review 2.  A systems approach to obesity.

Authors:  Bruce Y Lee; Sarah M Bartsch; Yeeli Mui; Leila A Haidari; Marie L Spiker; Joel Gittelsohn
Journal:  Nutr Rev       Date:  2017-01       Impact factor: 7.110

Review 3.  The 2009 H1N1 influenza pandemic: a case study of how modeling can assist all stages of vaccine decision-making.

Authors:  Bruce Y Lee; Ann E Wiringa
Journal:  Hum Vaccin       Date:  2011-01-01

4.  The cost of an Ebola case.

Authors:  Sarah M Bartsch; Katrin Gorham; Bruce Y Lee
Journal:  Pathog Glob Health       Date:  2015-01-11       Impact factor: 2.894

5.  A systems approach to vaccine decision making.

Authors:  Bruce Y Lee; Leslie E Mueller; Carla G Tilchin
Journal:  Vaccine       Date:  2016-12-22       Impact factor: 3.641

6.  Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study.

Authors:  Jay V DePasse; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Mary Patricia Nowalk; Richard K Zimmerman; Shawn T Brown
Journal:  Am J Epidemiol       Date:  2017-05-01       Impact factor: 4.897

7.  Influenza vaccination coverage among school employees: assessing knowledge, attitudes, and behaviors.

Authors:  Marie A de Perio; Douglas M Wiegand; Scott E Brueck
Journal:  J Sch Health       Date:  2014-09       Impact factor: 2.118

8.  Quantifying the economic value and quality of life impact of earlier influenza vaccination.

Authors:  Bruce Y Lee; Sarah M Bartsch; Shawn T Brown; Philip Cooley; William D Wheaton; Richard K Zimmerman
Journal:  Med Care       Date:  2015-03       Impact factor: 2.983

9.  Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study.

Authors:  Jay V DePasse; Mary Patricia Nowalk; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Richard K Zimmerman; Shawn T Brown
Journal:  Vaccine       Date:  2017-06-09       Impact factor: 3.641

10.  Policies to reduce influenza in the workplace: impact assessments using an agent-based model.

Authors:  Supriya Kumar; John J Grefenstette; David Galloway; Steven M Albert; Donald S Burke
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.